Annual General Meeting
2013
OBJ LimitedLeaders in magnetic enhanced drug delivery technology, products and solutions
For
per
sona
l use
onl
y
DDisclaimerisThis Presentation has been prepared by OBJ Limited (ABN 72 056 482 636) (OBJ or the Company). This Presentation contains summary information aboutOBJ and its activities current as at the date of this Presentation. The information in this Presentation is of general background and does not purport to becomplete or to comprise all the information that a shareholder or potential investor in OBJ may require in order to determine whether to deal in OBJshares. It should be read in conjunction with OBJ’s other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange(ASX), which are available at www.asx.com.au. This document is not a prospectus or a product disclosure statement under the Corporations Act (Cth) 2001(Corporations Act) and has not been lodged with the Australian Securities and Investments Commission (ASIC).Past performance information given in this Presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication offuture performance.This Presentation contains certain “forward‐looking statements”. The words “expect”, “should”, “could”, “may”, “will, “predict”, “plan”, “scenario”,“forecasts”, “anticipates”, “outlook” and other similar expressions are intended to identify forward‐looking statements. Indications of, and guidance on,future earnings and financial position and performance are also forward‐looking statements. Where the Company expresses or implies an expectation orbelief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis. Forward‐lookingstatements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice,as are statements about market and industry trends, which are based on interpretations of current market conditions. Such forward‐looking statementsincluding projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication orguarantee of future performance. There can be no assurance that actual outcomes will not differ materially from these forward‐looking statements, andthere are risks associated with the Company and the industry (including those set out below) which may affect the accuracy of the forward‐lookingstatements. The Company does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events orcircumstances after the date of this presentation, or to reflect the occurrence of unanticipated events, except as may be required under applicablesecurities laws.This document may not be released or distributed in the United States. This Presentation does not constitute an offer to sell, or the solicitation of an offerto buy, any securities in the United States. Securities in the Company have not been, and will not be, registered under the U.S. Securities Act of 1933 or thesecurities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States unless the securities are registeredunder the Securities Act or pursuant to an exemption from, or in a transaction not subject to, registration.
To the maximum extent permitted by law, OBJ and its respective advisers and affiliates, directors, officers and employees make no representation orwarranty, express or implied, as to the accuracy, reliability or completeness of information in the Presentation.F
or p
erso
nal u
se o
nly
Developing and partnering the creation of next generation products in
Cosmetics and Skincare, Consumer Healthcare, Oral Health and Pharmaceutical Products
For
per
sona
l use
onl
y
Highlights of 2013 Procter & Gamble
Following completion of a clinical study into the effect of OBJ’s magnetic microarray technology, P&G and OBJ are in negotiation regarding the possible product development of the first application for OBJ’s technology within P&G’s product range.
For
per
sona
l use
onl
y
Highlights of 2013 Coty and Philosophy
Philosophy completed a large clinical efficacy study using OBJ’s powered technology during 2013.
In response to the outcomes, Philosophy and OBJ are currently negotiating a Product Development Agreement.
For
per
sona
l use
onl
y
Highlights of 2013 GlaxoSmithKline (Oral Health)
Completion of multiple ex‐vivo studies in the UK under the GSK Collaboration Agreement, the first in‐mouth studies in humans and more recent progress with additional key ingredient studies have resulted in a large clinical efficacy study to be undertaken in the UK.
For
per
sona
l use
onl
y
Highlights of 2013 GlaxoSmithKline (Pharmaceuticals)
Completion of the Phase 1 optimization program under the GSK Collaboration Agreement using OBJ’s Field‐in‐Motion technology has resulted in negotiations to expand into a larger Phase 2 program.
For
per
sona
l use
onl
y
OBJ’s Own Products ‐ BodyGuard
2013 has seen major progress in the Company’s Bodyguard programme with the first product currently under clinical trialing under the supervision of Professor Tony Wright.
Highlights of 2013
For
per
sona
l use
onl
y
Other Highlights
• Appointed Operations Manager to oversee production and manufacturing
• New test models and expertise has extended OBJ’s influence with partners
• Expenditure has been strictly contained.• Capital raising now ensures the Company is well capitalised to meet immediate needs.For
per
sona
l use
onl
y
For
per
sona
l use
onl
y
BODYGUARD PROJECT UPDATE George Tsadilas
OBJ F
or p
erso
nal u
se o
nly
DISCLAIMER This Presenta,on has been prepared by OBJ Limited (ABN 72 056 482 636) (OBJ or the Company). This Presenta,on contains summary informa,on about OBJ and its ac,vi,es current as at the date of this Presenta,on. The informa,on in this Presenta,on is of general background and does not purport to be complete or to comprise all the informa,on that a shareholder or poten,al investor in OBJ may require in order to determine whether to deal in OBJ shares. It should be read in conjunc,on with OBJ’s other periodic and con,nuous disclosure announcements lodged with the Australian Securi,es Exchange (ASX), which are available at www.asx.com.au. This document is not a prospectus or a product disclosure statement under the Corpora,ons Act (Cth) 2001 (Corpora,ons Act) and has not been lodged with the Australian Securi,es and Investments Commission (ASIC). Past performance informa,on given in this Presenta,on is given for illustra,ve purposes only and should not be relied upon as (and is not) an indica,on of future performance. This Presenta,on contains certain “forward-‐looking statements”. The words “expect”, “should”, “could”, “may”, “will, “predict”, “plan”, “scenario”, “forecasts”, “an,cipates”, “outlook” and other similar expressions are intended to iden,fy forward-‐looking statements. Indica,ons of, and guidance on, future earnings and financial posi,on and performance are also forward-‐looking statements. Where the Company expresses or implies an expecta,on or belief as to future events or results, such expecta,on or belief is expressed in good faith and believed to have a reasonable basis. Forward-‐looking statements, opinions and es,mates provided in this Presenta,on are based on assump,ons and con,ngencies which are subject to change without no,ce, as are statements about market and industry trends, which are based on interpreta,ons of current market condi,ons. Such forward-‐looking statements including projec,ons, guidance on future earnings and es,mates are provided as a general guide only and should not be relied upon as an indica,on or guarantee of future performance. There can be no assurance that actual outcomes will not differ materially from these forward-‐looking statements, and there are risks associated with the Company and the industry (including those set out below) which may affect the accuracy of the forward-‐looking statements. The Company does not undertake any obliga,on to release publicly any revisions to any forward looking statement to reflect events or circumstances a_er the date of this presenta,on, or to reflect the occurrence of unan,cipated events, except as may be required under applicable securi,es laws. This document may not be released or distributed in the United States. This Presenta,on does not cons,tute an offer to sell, or the solicita,on of an offer to buy, any securi,es in the United States. Securi,es in the Company have not been, and will not be, registered under the U.S. Securi,es Act of 1933 or the securi,es laws of any state or other jurisdic,on of the United States, and may not be offered or sold in the United States unless the securi,es are registered under the Securi,es Act or pursuant to an exemp,on from, or in a transac,on not subject to, registra,on. To the maximum extent permibed by law, OBJ and its respec,ve advisers and affiliates, directors, officers and employees make no representa,on or warranty, express or implied, as to the accuracy, reliability or completeness of informa,on in the Presenta,on.
For
per
sona
l use
onl
y
OVERVIEW
• Develop a musculoskeletal patch to address the increasing incidence of of knee pain resulting from degrading cartilage in active people
• Expedite the commercialisation pathway by developing a market ready product for (a) partnering with a global consumer company or (b) OBJ to launch independently
For
per
sona
l use
onl
y
FORMULATION
• Formulation has been optimised to support synovial fluid function • Developed in conjunction with London School of Pharmacology • Registered trade name of Lubricen • Active ingredients are complimented by a permeation enhancer
Chondroitin Sulfate Glycosaminoglycan
Link Protein Hyaluronic Acid backbone
For
per
sona
l use
onl
y
TRANSDERMAL DELIVERY
• Large molecular weight of active ingredients require an intervening force to penetrate the body’s epidermal layers
• OBJ’s ETP has shown to be significantly more effective at delivering these active ingredients.
For
per
sona
l use
onl
y
MARKET VALIDATION
0-‐2 Not
interested
3-‐4 Fairly
uninterested
5
6-‐7 Quite
interested
8-‐10 Extremely interested
9 7 9 24 51
% Interest in Product Concept
• Extensive research conducted: Quantitative (3,000 UK and 1,000 AUS respondents) and Qualitative (8 focus groups in UK)
• A substantial market of knee pain sufferers exists • Significant interest in the product concept and for trial purchase • GP’s and Physios emerged as the key influencers
For
per
sona
l use
onl
y
DESIGN & PROTOTYPE
• Partnered with Design & Industry to design and engineer prototypes • Two product directions taken to appeal to a range of lifestyles • Low cost disposable adhesive patch • Durable strap with a recurring consumable - formulation pods
encapsulated in a technology module
For
per
sona
l use
onl
y
PRODUCT TRIAL
• Study to test product efficacy and consumer perceptions • Protocol and study methodology developed by Professor Tony Wright • 20 x active 40-55 year old males with knee pain • Baseline ALF testing then retest after product intervention
For
per
sona
l use
onl
y
THANK YOU
OBJ F
or p
erso
nal u
se o
nly